GlassScriptPhysician profile
Kenneth D Pugar
NPI 1174961874
$22,958.81
in general payments reported to CMS, 2019-2025
70 companies · $3,120 in 2025
The $3,120 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,025 · 2020: $1,592 · 2021: $3,179 · 2022: $5,529 · 2023: $3,254 · 2024: $3,260 · 2025: $3,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,530 · Education: $75.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,530.14 |
| Education | $75.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,519.95 | 2019-2025 | |
| Abbvie INC. | $2,387.16 | 2019-2025 | |
| Emd Serono, INC. | $1,760.20 | 2019-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,501.12 | 2019-2025 | |
| Mdd US Operations, LLC | $1,375.59 | 2021-2025 | Gocovri, Gocovri, Apokyn |
| Supernus Pharmaceuticals, INC. | $1,005.23 | 2019-2022 | |
| Ucb, INC. | $1,002.63 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Sk Life Science, INC. | $838.85 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $736.26 | 2019-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $692.59 | 2019-2025 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $663.32 | 2019-2025 | Ultomiris, Soliris |
| Allergan, INC. | $642.94 | 2019-2022 | |
| Amgen INC. | $511.19 | 2019-2024 | Aimovig |
| Lilly USA, LLC | $511.14 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Acorda Therapeutics, INC | $472.49 | 2019-2024 | Inbrija, Ampyra |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $419.60 | 2020-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $366.18 | 2019-2025 | |
| Lundbeck LLC | $364.56 | 2019-2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $353.96 | 2020-2021 | |
| Genentech USA, INC. | $352.83 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amneal Pharmaceuticals LLC | $342.31 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Insightec,INC | $320.62 | 2023-2025 | Exablate |
| Pfizer INC. | $281.07 | 2022-2025 | |
| Argenx US, INC. | $238.99 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Horizon Therapeutics Plc | $210.15 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $196.92 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $180.23 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $177.64 | 2022 | |
| Acadia Pharmaceuticals INC | $177.02 | 2019-2024 | Nuplazid |
| Greenwich Biosciences, INC. | $173.36 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $169.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.81 | 2023-2025 | Hyqvia, Gammagard |
| Neurelis, INC. | $137.38 | 2020-2025 | Valtoco |
| Adamas Pharmaceuticals, INC. | $122.84 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $118.64 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $109.10 | 2023 | Relyvrio |
| Alnylam Pharmaceuticals INC. | $101.90 | 2020-2022 | |
| Neuropace, INC. | $92.39 | 2024 | |
| Zyla Life Sciences, INC. | $83.25 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $81.14 | 2023-2024 | Aptiom |
| Ge Healthcare | $74.22 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $70.13 | 2023-2024 | Nuedexta, Rexulti |
| Celgene Corporation | $69.98 | 2022-2023 | Zeposia |
| Octapharma USA, INC. | $66.94 | 2022-2025 | Panzyga |
| Harmony Biosciences LLC | $64.50 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $62.89 | 2023-2025 | Dysport |
| Astrazeneca Pharmaceuticals LP | $53.58 | 2021-2025 | Wainua |
| Akcea Therapeutics, INC. | $47.93 | 2019-2020 | |
| Grifols USA, LLC | $41.82 | 2025 | Gamunex-C |
| Merz Pharmaceuticals, LLC | $41.02 | 2025 | Xeomin, Inbrija, Ampyra |
| Kyowa Kirin, INC. | $39.33 | 2021-2024 | Nourianz |
| Sanofi-Aventis U.S. LLC | $34.54 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $32.49 | 2022-2023 | Onzetra Xsail |
| Medtronic, INC. | $31.95 | 2021-2022 | |
| Sandoz INC. | $25.53 | 2024 | |
| Averitas Pharma INC. | $24.72 | 2023 | Qutenza |
| Portola Pharmaceuticals, LLC | $23.64 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $20.67 | 2023 | Spritam |
| Tg Therapeutics, INC. | $18.96 | 2024 | |
| Csl Behring | $18.85 | 2019 | |
| Impel Pharmaceuticals INC. | $18.19 | 2023 | Trudhesa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.97 | 2025 | Rexulti |
| Cala Health, INC. | $16.54 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $16.46 | 2023 | Fycompa |
| Promius Pharma LLC | $16.45 | 2019 | |
| Alfasigma USA, INC. | $15.85 | 2022 | |
| Corium, LLC | $15.40 | 2023 | Adlarity |
| Springworks Therapeutics, INC. | $15.04 | 2025 | Gomekli |
| Janssen Pharmaceuticals, INC | $13.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Pugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.